[{"id":"4d1b1ad0-482f-4a90-8155-1af97676acb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379647","created_at":"2022-05-18T11:56:57.534Z","updated_at":"2024-07-02T16:36:10.272Z","phase":"Phase 1","brief_title":"Natural Killer (NK) Cell Therapy for B-Cell Malignancies","source_id_and_acronym":"NCT05379647","lead_sponsor":"Zhejiang University","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • fludarabine IV • QN-019a"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-18"}]